References
- Rubio-Guerra AF, Vargas-Robles H, Vargas-Ayala G, Escalante-Acosta BA. Correlation between circulating adhesion molecule levels and albuminuria in type-2 diabetic normotensive patients. Med Sci Monit 2007; 13: CR349–CR352
- De Winter MPJ, Kanters E, Kraal G, Hofker MH. Nuclear factor kB signaling in atherogenesis. Arterioscler Thromb Vasc Biol. 2005; 25: 904–914
- Ghanem FA, Movahed A. Inflammation in high blood pressure: A clinical perspective. J Am Soc Hypertens. 2007; 1: 113–119
- Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105: 1135–1143
- Galen FX. Cell adhesion molecules in hypertension: Endothelial markers ofvascular injury and predictors of target organ damage?. J Hypertens. 2002; 20: 813–816
- Hwang S-J, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: The Atherosclerosis Risk In Communities (ARIC) Study. Circulation. 1997; 96: 4219–4225
- Boulbou MS, Koukoulis GN, Makri ED, Petinaki EA. Gourgoulianis KI,Germenis AE. Circulating adhesion molecules in type 2 diabetes mellitus and hypertension. Int J Cardiol. 2005; 98: 39–44
- Hansson GK. Inflammation, atherosclerosis and coronary artery disease. N Engl J Med. 2005; 352: 1685–1695
- Gasic S, Wagner O, Fasching P, Ludwig C, Veitl M, Kapiotis S, Jilma B. Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type 2 diabetic patients with microalbuminuria. Am J Hypertens. 1999; 12: 217–222
- Park JK, Fiebeler A, Muller DN, et al. Lacidipine inhibits adhesion molecule and oxidase expression independent of blood pressure reduction in angiotensin-induced vascular injury. Hypertension. 2002; 39: 680–689
- The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension. J Hypertens. 2007; 25: 105–188
- American Diabetes Association. Diagnosis and classification of diabetesmellitus. Diabetes Care. 2006; 29: S43–S48
- Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol. 2005; 25: 29–38
- Rosei EA, Rizzoni D, Muiesan NL, Sleiman I, Salvetti M, Monteduro C. Effects of candesartán cilexetil and enalapril on inflammatory markers ofatherosclerosis in hypertensive patients with non-insulin-dependent diabetesmellitus. J Hypertens. 2005; 33: 435–444
- Lin L, Chu Y, Fink GF, Engelhardt JF, Heistad DD, Chen AF. Endothelin-1 stimulates arterial VCAM-1 expression via NADPH oxidase-derived superoxide in mineralocorticoid hypertension. Hypertension. 2003; 42: 997–1003
- Callera GE, Montezano AC, Touyz RM, et al. ETa receptor mediated altered leucocyte-endothelial cell interaction and adhesion molecules expression in DOCA-salt rats. Hypertension. 2004; 43: 872–879
- Goto K, Kasuya Y, Matsuki N, et al. Endothelin activates the dihydropyridine-sensitive, voltage-dependent Ca2+ channel in vascular smooth muscle. Proc Natl Acad Sci. 1989; 86: 3915–3918
- Yamagushi M, Suwa H, Miyasaka M, Kumada K. Selective inhibition of vascular cell adhesion molecule-1 expression by verapamil in human vascular endothelial cells. Transplantation. 1997; 63: 759–764
- Rubio AF, Arceo A, Vargas G, Rodríguez L, Lozano JJ, Treviño C. The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes. Diabetes Care. 2004; 27: 1688–1691
- Rubio-Guerra AF, Lozano-Nuevo JJ, Vargas-Ayala G, et al. Efficacy of a fixed-dose combination of trandolapril-verapamil in obese hypertensive patients resistant to monotherapy. Clin Exp Hypertens. 2006; 28: 619–624
- Siragy HM, Xue C, Webb RL. Beneficial effects of combined benazepril-amlodipine on cardiac nitric oxide, cGMP, and TNF-α production after cardiac ischemia. J Cardiovasc Pharmacol. 2006; 47: 636–642